[Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?]

Hipertens Riesgo Vasc. 2016 Oct-Dec;33(4):123-125. doi: 10.1016/j.hipert.2016.10.001.
[Article in Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypoglycemic Agents / therapeutic use
  • PCSK9 Inhibitors
  • Prognosis
  • Risk Factors

Substances

  • Antibodies, Monoclonal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypoglycemic Agents
  • PCSK9 Inhibitors
  • PCSK9 protein, human